KR20220105158A - 이식유전자 발현의 drg-특이적 감소를 위한 조성물 - Google Patents

이식유전자 발현의 drg-특이적 감소를 위한 조성물 Download PDF

Info

Publication number
KR20220105158A
KR20220105158A KR1020227016895A KR20227016895A KR20220105158A KR 20220105158 A KR20220105158 A KR 20220105158A KR 1020227016895 A KR1020227016895 A KR 1020227016895A KR 20227016895 A KR20227016895 A KR 20227016895A KR 20220105158 A KR20220105158 A KR 20220105158A
Authority
KR
South Korea
Prior art keywords
sequence
seq
hidua
nucleotides
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227016895A
Other languages
English (en)
Korean (ko)
Inventor
줄리에트 호르도
제임스 엠. 윌슨
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/067872 external-priority patent/WO2020132455A1/en
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Publication of KR20220105158A publication Critical patent/KR20220105158A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
KR1020227016895A 2019-10-23 2020-10-22 이식유전자 발현의 drg-특이적 감소를 위한 조성물 Pending KR20220105158A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962924970P 2019-10-23 2019-10-23
US62/924,970 2019-10-23
US201962934915P 2019-11-13 2019-11-13
US62/934,915 2019-11-13
USPCT/US2019/067872 2019-12-20
PCT/US2019/067872 WO2020132455A1 (en) 2018-12-21 2019-12-20 Compositions for drg-specific reduction of transgene expression
US202062972404P 2020-02-10 2020-02-10
US62/972,404 2020-02-10
US202063005894P 2020-04-06 2020-04-06
US63/005,894 2020-04-06
US202063023602P 2020-05-12 2020-05-12
US63/023,602 2020-05-12
US202063038514P 2020-06-12 2020-06-12
US63/038,514 2020-06-12
US202063043600P 2020-06-24 2020-06-24
US63/043,600 2020-06-24
PCT/US2020/056881 WO2021081217A1 (en) 2019-10-23 2020-10-22 Compositions for drg-specific reduction of transgene expression

Publications (1)

Publication Number Publication Date
KR20220105158A true KR20220105158A (ko) 2022-07-26

Family

ID=75620360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227016895A Pending KR20220105158A (ko) 2019-10-23 2020-10-22 이식유전자 발현의 drg-특이적 감소를 위한 조성물

Country Status (8)

Country Link
US (1) US20220389457A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048785A4 (cg-RX-API-DMAC7.html)
JP (1) JP7697943B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220105158A (cg-RX-API-DMAC7.html)
AU (1) AU2020369570A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155154A1 (cg-RX-API-DMAC7.html)
IL (1) IL292372A (cg-RX-API-DMAC7.html)
WO (1) WO2021081217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298138A (en) * 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
US20230372539A1 (en) * 2020-08-24 2023-11-23 The Trustees Of The University Of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
KR20240100490A (ko) * 2021-10-18 2024-07-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물
AU2022379625A1 (en) * 2021-10-27 2024-05-16 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i
US20260000790A1 (en) * 2022-07-08 2026-01-01 Ospedale San Raffaele S.R.L. Transgene cassettes
CN116064593B (zh) * 2023-02-09 2024-05-14 四川大学 一种毛白杨pgag基因及其应用
WO2025188755A1 (en) * 2024-03-04 2025-09-12 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
KR20220082100A (ko) * 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
MA43968A (fr) * 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
CN108697774A (zh) * 2016-02-22 2018-10-23 北卡罗来纳大学教堂山分校 治疗mps i-相关失明的aav-idua载体
CA3068328A1 (en) * 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
DK3684423T5 (da) * 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
WO2021081217A1 (en) 2021-04-29
JP2022553406A (ja) 2022-12-22
EP4048785A1 (en) 2022-08-31
US20220389457A1 (en) 2022-12-08
IL292372A (en) 2022-06-01
CA3155154A1 (en) 2021-04-29
JP7697943B2 (ja) 2025-06-24
AU2020369570A1 (en) 2022-05-12
EP4048785A4 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
KR102697086B1 (ko) 척수근 위축증의 치료에 유용한 조성물
JP7697943B2 (ja) 導入遺伝子発現のdrg特異的低減のための組成物
AU2018335752B2 (en) Gene therapy for treating Mucopolysaccharidosis type ii
CN115803064A (zh) 用于drg特异性降低转基因表达的组合物
JP7637058B2 (ja) Grn関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
KR20250171426A (ko) I형 점액다당류증을 치료하기 위한 유전자 요법
KR102823833B1 (ko) 뮤코다당류증 iiia형에 대한 유전자 요법
AU2017250298A1 (en) Gene therapy for treating mucopolysaccharidosis type II
US20230270884A1 (en) Compositions useful for treatment of charcot-marie-tooth disease
KR20240063170A (ko) I형 점액다당류증을 치료하기 위한 유전자 요법
KR20200104864A (ko) 뮤코다당류증 iiib형에 대한 유전자 요법
KR20230118075A (ko) 파브리병 치료를 위한 조성물 및 방법
CN118401667A (zh) 用于治疗cdkl5缺乏症(cdd)的组合物
CN115916334A (zh) 可用于治疗庞贝病的组合物
KR20210132095A (ko) 크라베병의 치료에 유용한 조성물
KR20220145838A (ko) Gm1 강글리오사이드증을 치료하는 데 유용한 조성물
US20240401078A1 (en) Compositions useful for treatment of charcot-marie-tooth disease
CN116669774A (zh) 用于治疗法布里病的组合物和方法
AU2024320694A1 (en) Compositions and methods for treatment of spinal muscular atrophy
KR20230023637A (ko) 크라베병의 치료에 유용한 조성물
CA3205351A1 (en) Compositions and methods for treatment of niemann pick type a disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000